BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, is pleased to announce the Health Canada approval of MYALEPTA™ (metreleptin for injection). As an adjunct to diet, MYALEPTA is indicated as a...
Latest News
BOSTON, Mass. — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness wounds...
CARLTON, Mercer County — Kyle Bennett is a 4-year-old, and he looks and behaves as such. It’s all shy smiles at first, then he opens up to show you what he’s into — kid stuff like his puppy, fishing with Dad, games, Scooby Doo … and more Scooby Doo. Kyle...
Denver, Colorado – Four children who acquired HIV in utero have remained free of detectable HIV for more than one year, according to new findings that were presented on March 6, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colo. The study is part of ongoing, multinational...
Beijing, China – Colorectal cancer (CRC) is expected to contribute to a burden of 3.2 million new cases and 1.6 million deaths by 2040. CRC prevention strategies target lifestyle changes, screening high-risk individuals, and polyp removal, while the most effective treatment options are surgery and chemotherapy or radiotherapy. Although early...
Tang Dafeng began livestreaming on Douyin, the Chinese version of TikTok, at 10 pm, saying hello to the audience and introducing the story of her 3-year-old daughter, who two years ago was diagnosed with Rett syndrome, a rare disease that many people have never heard of. On Douyin, many mothers...
SEATTLE – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Tom Frohlich, chief business officer, has been promoted to chief operating officer (COO) of Chinook and Andrew King, D.V.M, Ph.D., head of renal discovery and translational...
Enrollment ongoing in atrasentan pivotal phase 3 ALIGN study in IgAN and phase 2 AFFINITY study in proteinuric glomerular diseases Chinook expects to present data from the IgAN patient cohort of the phase 2 AFFINITY study in the first half of 2022, with data from one or more additional cohorts expected...
CHENGDU, China — Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution. The trial is a multi-center,...
SOUTH PLAINFIELD, N.J. – PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months and older, with a clinical...